This content discusses how technology is transforming the life sciences, specifically focusing on AI adoption in clinical care. FDA Commissioner Robert Califf highlights the challenges of regulating AI devices and emphasizes the need for ongoing evaluation of AI tools in clinical settings. Amazon introduces upfront pricing in telehealth, potentially competing with companies like Hims. The DEA extends telemedicine prescriptions for controlled drugs like opioids and ADHD medications, sparking discussions about future regulations. Schrödinger, a company in the AI drug discovery field, rejects the AI label and discusses its unique approach. Overall, the content covers various developments and challenges in the intersection of healthcare and technology.
Source link
Califf cautions against adopting AI for financial reasons
